JP2017503756A5 - - Google Patents

Download PDF

Info

Publication number
JP2017503756A5
JP2017503756A5 JP2016533116A JP2016533116A JP2017503756A5 JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5 JP 2016533116 A JP2016533116 A JP 2016533116A JP 2016533116 A JP2016533116 A JP 2016533116A JP 2017503756 A5 JP2017503756 A5 JP 2017503756A5
Authority
JP
Japan
Prior art keywords
muscle activity
treatment
deuterium
abnormal muscle
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016533116A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017503756A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/066740 external-priority patent/WO2015077520A1/en
Publication of JP2017503756A publication Critical patent/JP2017503756A/ja
Publication of JP2017503756A5 publication Critical patent/JP2017503756A5/ja
Pending legal-status Critical Current

Links

JP2016533116A 2013-11-22 2014-11-21 異常な筋活動を処置する方法 Pending JP2017503756A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361907675P 2013-11-22 2013-11-22
US61/907,675 2013-11-22
PCT/US2014/066740 WO2015077520A1 (en) 2013-11-22 2014-11-21 Methods of treating abnormal muscular activity

Publications (2)

Publication Number Publication Date
JP2017503756A JP2017503756A (ja) 2017-02-02
JP2017503756A5 true JP2017503756A5 (cg-RX-API-DMAC7.html) 2018-01-11

Family

ID=53180159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016533116A Pending JP2017503756A (ja) 2013-11-22 2014-11-21 異常な筋活動を処置する方法

Country Status (8)

Country Link
US (1) US20160303110A1 (cg-RX-API-DMAC7.html)
EP (1) EP3071565A4 (cg-RX-API-DMAC7.html)
JP (1) JP2017503756A (cg-RX-API-DMAC7.html)
CA (1) CA2930167A1 (cg-RX-API-DMAC7.html)
HK (1) HK1224294A1 (cg-RX-API-DMAC7.html)
IL (1) IL245538A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016006622A (cg-RX-API-DMAC7.html)
WO (1) WO2015077520A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
NZ705372A (en) 2012-09-18 2018-07-27 Auspex Pharmaceuticals Inc Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
CA2930744A1 (en) 2013-12-03 2015-06-11 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
EP2918266A1 (en) * 2014-03-11 2015-09-16 CDRD Berolina AB Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
CN114796209A (zh) 2015-03-06 2022-07-29 奥斯拜客斯制药有限公司 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US10786202B2 (en) 2016-09-28 2020-09-29 International Business Machines Corporation Quantifying grip strength and characterizing movement idioms

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7367953B2 (en) * 2003-11-26 2008-05-06 Ge Medical Systems Global Technology Company Method and system for determining a period of interest using multiple inputs
USRE46555E1 (en) * 2006-02-17 2017-09-19 Teva Pharmaceuticals International Gmbh Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2007130365A2 (en) * 2006-05-02 2007-11-15 The Trustees Of The University Of Pennsylvania Radiolabeled dihydrotetrabenazine derivatives and their use as imaging agents
US8008500B2 (en) * 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
DK2674104T3 (en) * 2008-06-12 2015-06-29 Amygdala Pty Ltd Detection of hypokinetic and / or hyperkinetic conditions
US11016104B2 (en) * 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
NO3061760T3 (cg-RX-API-DMAC7.html) * 2008-09-18 2018-04-07
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
CA2801061A1 (en) * 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
US9676810B2 (en) * 2010-07-08 2017-06-13 The Brigham And Women's Hospital, Inc. Neuroprotective molecules and methods of treating neurological disorders and inducing stress granules
WO2013142816A1 (en) * 2012-03-23 2013-09-26 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders

Similar Documents

Publication Publication Date Title
JP2017503756A5 (cg-RX-API-DMAC7.html)
NZ721645A (en) Compounds for use as gpr120 agonists
BRPI0821994B8 (pt) composto ou um enantiômero, um diasteroisômero ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
JP2012526791A5 (cg-RX-API-DMAC7.html)
RU2010145459A (ru) Ингибиторы активности протеинтирозинкиназы
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
FI3738434T3 (fi) Välituotteita substituoitujen bentsaldehydiyhdisteiden saamiseksi ja menetelmiä niiden käyttöön kudosten hapetuksen lisäämiseksi
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
HRP20191617T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
ES2560676T3 (es) Combinación farmacéutica para el tratamiento del dolor
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
JP2015513557A5 (cg-RX-API-DMAC7.html)
MY189770A (en) Biaryl derivative as gpr120 agonists
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
BR112014005389A8 (pt) Sal cloridrato de 4- (3-metanossulfonil-fenil) -1- propil-piperidina em uma forma cristalina, composição farmacêutica compreendendo o mesmo e usos do dito sal
RU2008139315A (ru) Избирательные андрогенные рецепторные модуляторы
MX369956B (es) Metodos para preparar compuestos de benzoquinolina.
EA201071099A1 (ru) СОЛЕВЫЕ ФОРМЫ ИНГИБИТОРА mTOR
JP2014062126A5 (cg-RX-API-DMAC7.html)
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
EA201590735A1 (ru) 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112022008786A2 (pt) Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose
EA201591804A1 (ru) Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы